SCHEMBL3049934

SCHEMBL3049934

O=C(CNC(=O)c1ccc(S(=O)(=O)Nc2ccccc2Oc2ccccc2)cc1)NCCCN1CCC(N2CCCCC2)CC1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
CCR2 P41597 6/20 0.48
BDKRB1 P46663 2/20 0.47
KCNH2 Q12809 1/20 0.47
USP5 P45974 1/20 0.45
METAP2 P50579 1/20 0.44
CHRM4 P08173 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
HTT P42858 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
PKM P14618 1/20 0.42
GAA P10253 1/20 0.42
SLC2A1 P11166 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3148923 0.95 L3MBTL3 (0.52) L3MBTL3L3MBTL1CCR2BDKRB1KCNH2
SCHEMBL3050672 0.93 CCR2 (0.53) CCR2BDKRB1KCNH2MEN1KMT2A
SCHEMBL3144249 0.89 CCR2 (0.50) L3MBTL3L3MBTL1CCR2BDKRB1KCNH2
SCHEMBL3147720 0.87 CCR2 (0.52) L3MBTL3L3MBTL1CCR2KCNH2CHRM4
SCHEMBL3062074 0.87 CCR2 (0.57) CCR2KCNH2MEN1KMT2ASMN1; SMN2
SCHEMBL3153072 0.87 CCR2 (0.50) L3MBTL3L3MBTL1CCR2BDKRB1KCNH2
SCHEMBL3149074 0.85 CCR2 (0.59) L3MBTL3L3MBTL1CCR2KCNH2SMN1; SMN2
SCHEMBL15103777 0.85 USP5 (0.49) L3MBTL3L3MBTL1CCR2USP5KMT2A
SCHEMBL3059103 0.84 HSD17B10 (0.46) CCR2METAP2MEN1KMT2ASMN1; SMN2
SCHEMBL3149383 0.84 L3MBTL3 (0.44) L3MBTL3L3MBTL1CCR2BDKRB1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2057116-B1 NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-02-13 EP claimed
US-20120295910-A1 New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists BEKE GYULA (HU) 2012-11-22 US claimed
US-20100105686-A1 PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-04-29 US claimed
EP-2057116-B1 NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-02-13 EP disclosed
US-20130029991-A1 New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists BEKE GYULA (HU) 2013-01-31 US disclosed
US-20120295910-A1 New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists BEKE GYULA (HU) 2012-11-22 US disclosed
US-20100105686-A1 PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295910-A1 New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists BDKRB1, BDKRB2, HRH4 L3MBTL3 2470/4885L3MBTL1 1790/4885CCR2 390/4885
US-20130029991-A1 New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists BDKRB1, BDKRB2, HRH4 L3MBTL3 2115/4885L3MBTL1 1531/4885CCR2 371/4885
US-20100105686-A1 PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS BDKRB1, BDKRB2, HRH1 L3MBTL3 2004/4885L3MBTL1 1455/4885CCR2 359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.